Company news

Hoth Therapeutics, Inc. news in 2024

Hoth Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

December 25, 2024

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

November 19, 2024

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

October 28, 2024

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

October 14, 2024

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

September 16, 2024

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

September 4, 2024

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

September 4, 2024

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

August 14, 2024

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

July 15, 2024

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

June 9, 2024

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

March 26, 2024

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

March 18, 2024

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

February 28, 2024

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

February 25, 2024

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

January 17, 2024

Decks in 2024